Medtronic in vascular puncture haemostasis deal with Scion
This article was originally published in Clinica
Medtronic is to have exclusive distribution rights to Scion Cardio-Vascular's Clo-Sur PAD, used for the rapid control of bleeding from vascular access sites, and has made a minority equity in investment in the Miami, Florida-based company. Under the deal with Medtronic, use of the noninvasive device is limited to the control of bleeding following catheter removal associated with a catheterisation procedure, such as stenting, and other minimally invasive procedures.
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.